RSPO3/R-spondin-3 Protein, Human (HEK293, Fc-His)

RSPO3, a potent activator of the canonical Wnt pathway, binds to LGR4-6 receptors, initiating a complex with phosphorylated LRP6 and frizzled receptors. This interaction activates the canonical Wnt pathway, upregulating target genes. RSPO3, a multifaceted regulator, inhibits ZNRF3 and acts as a ligand for FZD8 and LRP6, potentially negatively regulating the TGF-beta pathway. In angiogenesis, RSPO3 controls vascular stability and pruning through the non-canonical Wnt pathway in endothelial cells. Notably, RSPO3 can amplify the Wnt pathway independently of LGR4-6 receptors, possibly by antagonizing RNF43 and ZNRF3. Interactions with FZD8, LRP6, WNT1, and LGR4-6 underscore its intricate role in Wnt signaling modulation. RSPO3/R-spondin-3 Protein, Human (HEK293, Fc-His) is the recombinant human-derived RSPO3/R-spondin-3 protein, expressed by HEK293, with C-hFc, C-6*His labeled tag. The total length of RSPO3/R-spondin-3 Protein, Human (HEK293, Fc-His) is 180 a.a., with molecular weight of ~61.0 kDa.

R-Spondin 3 (RSPO3) serves as a potent activator of the canonical Wnt signaling pathway, acting as a ligand for LGR4-6 receptors and playing a pivotal role in angiogenesis regulation. Upon binding to LGR4-6 (LGR4, LGR5, or LGR6), the resulting complex associates with phosphorylated LRP6 and frizzled receptors, activated by extracellular Wnt receptors. This interaction triggers the canonical Wnt signaling pathway, leading to an upregulation of target gene expression. RSPO3 also acts as a multifaceted regulator by inhibiting ZNRF3, a crucial component of the Wnt signaling pathway, and serving as a ligand for frizzled FZD8 and LRP6. It may additionally exert negative regulation on the TGF-beta pathway. In the context of angiogenesis, RSPO3 emerges as a key player, controlling vascular stability and pruning by activating the non-canonical Wnt signaling pathway in endothelial cells. Remarkably, RSPO3 exhibits the capability to amplify the Wnt signaling pathway independently of LGR4-6 receptors, possibly through direct antagonistic interactions with RNF43 and ZNRF3. Interactions with the extracellular domain of FZD8 and LRP6, along with binding to WNT1 and LGR4, LGR5, and LGR6, underscore the intricate regulatory mechanisms orchestrated by RSPO3 in Wnt signaling modulation.

Human

HEK293

C-hFc;C-6*His

Q9BXY4 (Q22-V201)

84870  [NCBI]

QNASRGRRQRRMHPNVSQGCQGGCATCSDYNGCLSCKPRLFFALERIGMKQIGVCLSSCPSGYYGTRYPDINKCTKCKADCDTCFNKNFCTKCKSGFYLHLGKCLDNCPEGLEANNHTMECVSIVHCEVSEWNPWSPCTKKGKTCGFKRGTETRVREIIQHPSAKGNLCPPTNETRKCTV

Approximately 61.0 kDa

Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US;may vary elsewhere.